618 related articles for article (PubMed ID: 11549484)
1. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
3. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
4. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
5. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
6. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
7. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
8. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
Ruoppolo M; Gozo M; Milesi R; Spina R; Fragapane G
Urologia; 2010; 77 Suppl 17():72-7. PubMed ID: 21308679
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results.
Bazarbashi S; Raja MA; El Sayed A; Ezzat A; Ibrahim E; Kattan S; Kardar A; Peracha A; Lindstedt E; Hanash K
J Surg Oncol; 2000 Jul; 74(3):181-4. PubMed ID: 10951412
[TBL] [Abstract][Full Text] [Related]
10. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
11. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
Fujimoto K; Chihara Y; Kondo H; Hirao Y
Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
Steinberg G; Bahnson R; Brosman S; Middleton R; Wajsman Z; Wehle M
J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
[TBL] [Abstract][Full Text] [Related]
14. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
Loertzer H; Brake M; Horsch R; Keller H
Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
17. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Robins DJ; Sui W; Matulay JT; Ghandour R; Anderson CB; DeCastro GJ; McKiernan JM
Urology; 2017 May; 103():149-153. PubMed ID: 28163086
[TBL] [Abstract][Full Text] [Related]
18. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
19. Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
Hillyard RW; Ladaga L; Schellhammer PF
J Urol; 1988 Feb; 139(2):290-3. PubMed ID: 3339727
[TBL] [Abstract][Full Text] [Related]
20. [Progression and recurrence in the prostate and upper urinary tract following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Wakabayashi Y; Okada Y; Mukumoto K; Hamaguchi A; Konishi T; Tomoyoshi T
Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2146-51. PubMed ID: 8309122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
